Forbion related stories
All articles and analysis
Fundraising recaps from around the worldFrom ffVC in New York to KfW in Germany, a summary of recent venture fundraising closes
Fonds de solidarité FTQ invests $9.5 mln in DalCor PharmaThe Fonds de solidarité FTQ has invested about $9.5 million (US$7.5 million) in DalCor Pharmaceuticals, a Montréal-based developer of precision treatments for cardiovascular disease. The investment formed part of the company's recently closed $100 million Series B financing /canada/2016/4/dalcor-pharmaceuticals/ DalCor, which emerged from research conducted at Montréal Heart Institute, is led by CEO Robert McNeil, the founder of U.S. life sciences venture capital firm Sanderling Ventures. The Fonds committed US$30 million to Sanderling Ventures Fund VII in September 2013.
Knight Therapeutics commits to Forbion's third life sciences fundEuropean life sciences venture capital firm Forbion Capital Partners has closed its third fund, Forbion Capital Fund III (FCF III), at 183 million euros (US$208 million). Among the fund's limited partners was strategic investor Knight Therapeutics Inc (TSX: GUD), a Canadian specialty pharmaceutical company. Early last year, Forbion led the $13.5 million Series B financing /canada/2015/1/intestinal-gene-delivery-platform-egene-nets-13-5-mln-in-series-b-round/ of enGene Inc, a Montréal-based developer of novel DNA-based therapeutics.
Forbion Capital Fund III closes at $208 mlnForbion Capital Partners said April 12 that its third main fund, Forbion Capital Fund III, closed at 183 million euros ($208 million). Investors of FCF III include the European Investment Fund (EIF), the Dutch Venture Initiative (DVI), Germany’s KfW development bank, various other regional investment agencies, pension funds, insurance companies, leading European family offices and two strategic investors: Charles River Laboratories and Knight Therapeutics. The fund will invest in private companies developing novel drugs, medical devices and diagnostics for high, or even unmet, medical needs.
- Akarna Therapeutics closes $15 mln Series B
Drug developer Akarna Therapeutics Ltd raised $15 million in a Series B preferred stock financing round. New investor Forbion Capital Partners joined existing backers New Science Ventures and Third Point Ventures to complete the round.
- Exosome Diagnostics grabs $60 mln Series B
Cambridge, Massachusetts-based Exosome Diagnostics Inc, a liquid biopsy platform developer, has raised $60 million in Series B funding. The investors included Forbion Capital Partners, NGN Capital, CD Ventures, Qiagen, Arcus Ventures, Tiger Management and Blue Ridge Capital.
- Replimune reels in $30 mln Series A
UK-based Replimune, a developer of oncolytic immunotherapy, has secured $30 million in Series A funding. Atlas Venture led the round with participation from return backers Forbion Capital Partners and Omega Funds. In addition to the funding, Jason Rhodes of Atlas, Otello Stampacchia of Omega and Sander Slootweg of Forbion have been added to Replimune's board.
Fundraising recap Sep 21, 2015San Francisco-based firm seeks cloud business apps; 500 closes one fund and plans another; and other fundraising briefs worldwide
- Amgen to acquire Forbion-backed Dezima for up to $1.55 bln
Amgen Inc has agreed to buy Dezima Pharma from Forbion Capital Partners and other shareholders for up to $1.55 billion. Also included in the deal is an upfront payment of $300 million. Based in The Netherlands, Dezima develops drugs that treat dyslipidemic patients suffering from cardiovascular disease.
- Forbion FCF II Co-invest Fund I closes at $84 mln
Forbion Capital Partners said it closed its Forbion Capital Fund II Co-invest Fund I with 75 million Euros (US$84 million). The Co-Invest fund was set up to allow Forbion’s existing LPs to back later-stage, de-risked companies within the existing FCF II portfolio with additional (growth) capital. The pool will invest in up to six existing FCF II portfolio companies, alongside FCF II. Forbion is a Life Sciences venture capital firm with offices in Naarden, The Netherlands